Phaseline

Companies › AbbVie

AbbVie: clinical trials, targets and expected readouts

74 active drug programs in 582 registered trials: 267 Phase 2, 181 Phase 1, 94 Phase 3, 40 Phase 4; Oncology, Other, Immunology, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Venetoclax
Apoptosis regulator Bcl-2 inhibitor
BCL2Phase 4Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia; Myelodysplastic Syndrome (MDS); Chronic Lymphocytic Leukemia …Nov 2026
OnabotulinumtoxinA
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 4Jawline and Neck Appearance; Urinary Bladder, Overactive; Overactive Bladder; Trigeminal Neuralgia …Jun 2027
Azacitidine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 4Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)Jul 2027
Mirvetuximab Soravtansine
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 3Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer …Nov 2026
Obinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia (CLL)Nov 2026
Upadacitinib
Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
TYK2, JAK3, JAK2, JAK1Phase 3Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease …Nov 2026
ABBV-RGX-314 (surabgene lomparvovec, RGX-314)
AAV8 vector containing a transgene for anti-VEGF Fab
VEGFAPhase 3AMD; Neovascular Age-related Macular Degeneration; Diabetic Retinopathy (DR); Neovascular Age-Related Macular Degeneration (nAMD) …Dec 2026
Lutikizumab
Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor
IL1A, IL1BPhase 3Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis …Dec 2026
Navitoclax
Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor
BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1Phase 3Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma …Dec 2026
Risankizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) …Jan 2027
ABBV-383 (Etentamig)
BCMA-directed bispecific antibody
BCMAPhase 3Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; Immunoglobulin Light Chain (AL) AmyloidosisFeb 2027
Cariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3DepressionMar 2027
Ubrogepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Migraine; Healthy VolunteerMay 2027
Atogepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Menstrual Migraine (MM); Episodic Migraine; Chronic MigraineJul 2027
Elagolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Endometriosis; Menopause; InfertilityJul 2027
Telisotuzumab adizutecan
Anti-MET antibody-drug conjugate
METPhase 3Colorectal Cancer; Metastatic Colorectal Cancer; Pancreatobiliary Cancers; Head and Neck Squamous Cell Carcinoma …Jul 2027
ABBV-706
Delta-like ligand 3 (DLL3) targeted therapy
DLL3Phase 3Small Cell Lung Cancer; Advanced Solid TumorsNov 2027
Telisotuzumab Vedotin (ABBV-399)
Tubulin inhibitor; Hepatocyte growth factor receptor binding agent
Tubulin, METPhase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer …Feb 2028
NOA LIFT
hyaluronic acid-based dermal filler
–Phase 3Nasolabial FoldsAug 2028
XEN63 Glaucoma Treatment System
Gel stent for intraocular pressure reduction
–Phase 3Primary Open Angle GlaucomaNov 2028
NOA VOLUME
Crosslinked hyaluronic acid injectable gel
–Phase 3Mid Face Volume DeficitJul 2029
ELAPR002f Injectable Gel
Space-occupying dermal filler for atrophic acne scars
–Phase 3Acne ScarsNov 2029
ABBV-1480–Phase 3Non-Small Cell Lung CancerDec 2029
Lidocaine
Sodium channel alpha subunit blocker
Ion channelsPhase 3Mid Face Volume Deficit; Blood Gas Analysis; Hemiplegia; Rib Fractures …–
ABBV-701
Undisclosed mechanism (code-named investigational drug)
–Phase 2Crohn's Disease; Healthy VolunteerNov 2026
ABBV-932–Phase 2Generalized Anxiety Disorder (GAD); Bipolar I or II Disorder; Healthy Volunteer; Bipolar DisorderNov 2026
Budigalimab (ABBV-181)
Programmed cell death protein 1 inhibitor
PDCD1Phase 2Hepatocellular Carcinoma; Urothelial Carcinoma; Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Non-Small Cell Lung Cancer …Nov 2026
Livmoniplimab–Phase 2Hepatocellular Carcinoma; Urothelial Carcinoma; Non-Small Cell Lung Cancer; Hepatocellular Carcinoma (HCC) …Nov 2026
ABBV-400–Phase 2Unresectable Metastatic Colorectal Cancer; Hepatocellular Carcinoma; Non-Small Cell Lung CancerDec 2026
Emraclidine
Muscarinic acetylcholine receptor agonist
–Phase 2Schizophrenia; Healthy VolunteerDec 2026
Pivekimab Sunirine
Interleukin-3 receptor subunit alpha binding agent
IL3RAPhase 2Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell NeoplasmDec 2026
ABBV-295
amylin analog
CALCRPhase 2Obesity; Healthy VolunteerJan 2027
IMGN151
anti-FOLR1 antibody-drug conjugate
FOLR1Phase 2Gynecologic Cancers; Endometrial CancerFeb 2027
MEDI0618
CALCA receptor antagonist
–Phase 2MigraineFeb 2027
Ravagalimab
CD40 ligand antagonist
CD40LGPhase 2Rheumatoid ArthritisFeb 2027
Trenibotulinumtoxine (AGN-151586)
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 2Forehead Lines; Upper Facial Lines; Glabellar LinesFeb 2027
Armour Thyroid
Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3)
THRA, THRBPhase 2HypothyroidismSep 2027
Icalcaprant–Phase 2Major Depressive Disorder; Bipolar I DisorderSep 2027
AGN-151607-DP–Phase 2Ventral Hernia; Upper Limb Essential TremorSep 2028
ABBV-142–Phase 2Idiopathic Pulmonary FibrosisSep 2029
ABBV-8736–Phase 2Crohn's DiseaseJan 2030
Trosunilimab–Phase 2Crohn's DiseaseJan 2030
Tofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 1Healthy VolunteersDec 2026
ABBV-291–Phase 1Non-Hodgkin's LymphomaJan 2027
ABBV-744–Phase 1Myelofibrosis (MF)Jan 2027
ABBV-319
B cell depletion
–Phase 1Diffuse Large B-Cell Lymphoma; Dry Eye SyndromeFeb 2027
ABBV-859–Phase 1Healthy VolunteerFeb 2027
ABBV-368–Phase 1CancerMar 2027
Giloralimab (ABBV-927)
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Advanced Solid Tumors Cancer; CancerMar 2027
ABBV-1451–Phase 1Healthy VolunteerApr 2027
ABBV-243–Phase 1Healthy VolunteersMay 2027
ABBV-7828–Phase 1Healthy SubjectsMay 2027
ABBV-969–Phase 1Metastatic Castration-Resistant Prostate CancerMay 2027
ABBV-453–Phase 1Relapsed/Refractory Multiple Myeloma; Chronic Lymphocytic LeukemiaJul 2027
Azirkitug
CD40 agonist monoclonal antibody
CD40Phase 1Non-Small Cell Lung CancerJul 2027
ABBV-313–Phase 1Healthy VolunteersFeb 2028
ABBV-547–Phase 1Healthy VolunteerMay 2028
ABBV-901
Unclear - investigational cancer therapeutic
–Phase 1Ovarian CancerDec 2028
ABBV-519–Phase 1Systemic Lupus ErythematosusJan 2029
ABBV-711–Phase 1Advanced Squamous TumorsApr 2029
AGN-193408 SR
Prostaglandin analog (implant formulation)
–Phase 1Open-angle GlaucomaApr 2029
ABBV-525–Phase 1Diffuse Large B-Cell LymphomaJul 2029
ABBV-6628
Monoclonal antibody fragment
–Phase 1Geographic AtrophyOct 2029
ABBV-253–Phase 1Advanced Solid TumorsDec 2029
ABBV-324–Phase 1Hepatocellular CancerSep 2030
ABBV-1758–Phase 1Alzheimer's DiseaseOct 2030
Surzetoclax
BCL2 family protein inhibitor
BCL2L1Phase 1Multiple MyelomaDec 2030
ABBV-101–Phase 1Hematologic CancerMar 2031
ABBV-438–Phase 1Multiple MyelomaNov 2031
ABBV-2001
T cell engaging bi/tri-specific antibody
–Phase 1Multiple MyelomaDec 2035
ABBV-1042–Phase 1Healthy Volunteer–
ABBV-637–Phase 1Advanced Solid Tumors Cancer; Glioblastoma–
Nacresertib–Phase 1Healthy Volunteer–
TNB-383B
BCMA x CD3 T-cell engaging bispecific antibody
BCMA, CD3EPhase 1Multiple Myeloma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03675308RisankizumabPhase 3Psoriatic ArthritisImmunologyOct 2020
NCT04305743OnabotulinumtoxinAPhase 4Urinary Bladder, OveractiveGenitourinaryJan 2021
NCT04020510OnabotulinumtoxinAPhase 4Overactive BladderGenitourinaryJul 2021
NCT02993523VenetoclaxPhase 3Acute Myeloid Leukemia (AML)OncologyDec 2021
NCT03064867VenetoclaxPhase 1Diffuse Large B-cell-lymphomaOncologyAug 2022
NCT04476199VenetoclaxPhase 2Acute Myeloid LeukemiaOncologyFeb 2023
NCT05308654ABBV-453Phase 1Relapsed/Refractory Multiple MyelomaOncologyFeb 2024
NCT04763928VenetoclaxPhase 2Acute Myeloid LeukemiaOncologyOct 2024
NCT05996406VenetoclaxPhase 2Light Chain (AL) AmyloidosisMetabolic and endocrineNov 2024
NCT06918340LidocainePhase 4Blood Gas AnalysisOtherDec 2024
NCT05358639NavitoclaxPhase 1High Grade Serous CarcinomaOncologyMar 2025
NCT05260125LidocainePhase 4HemiplegiaNeurologyMar 2025
NCT04905810VenetoclaxPhase 2Acute Myeloid LeukemiaOncologyMay 2025
NCT06310200LidocainePhase 1Cold Induced HeadacheNeurologyMay 2025
NCT04817241VenetoclaxPhase 1Acute Myeloid LeukemiaOncologyJun 2025
NCT04572763VenetoclaxPhase 1Diffuse Large B Cell LymphomaOncologyJul 2025
NCT06519929LidocainePhase 4Rib FracturesOtherAug 2025
NCT06928376VenetoclaxPhase 2Acute Myeloid LeukemiaOncologySep 2025
NCT04075981OnabotulinumtoxinAPhase 3Cardiac SurgeryCardiovascularOct 2025
NCT05833438VenetoclaxPhase 2Acute Myeloid Leukemia (AML)OncologyNov 2025
NCT06121466LidocainePhase 4Anterior Cutaneous Nerve Entrapment SyndromeNeurologyDec 2025
NCT06391125LidocainePhase 3Syphilis InfectionInfectious diseaseDec 2025
NCT07000058LidocainePhase 2Hand SurgeryOtherDec 2025
NCT05881265VenetoclaxPhase 2APLOncologyJan 2026
NCT05870995VenetoclaxPhase 2Refractory LeukemiaOncologyFeb 2026
NCT04721015ABBV-637Phase 1Advanced Solid Tumors CancerOncologyFeb 2026
NCT07039877VenetoclaxPhase 2Acute Lymphobkastic LeukemiaOncologyFeb 2026
NCT05901974VenetoclaxPhase 2Acute Leukemia of Ambiguous LineageOncologyMar 2026
NCT05144243VenetoclaxPhase 4Acute Myeloid Leukemia (AML)OncologyMar 2026
NCT05144243AzacitidinePhase 4Acute Myeloid Leukemia (AML)OncologyMar 2026
NCT05286229ABBV-383 (Etentamig)Phase 1Relapsed/Refractory Multiple MyelomaOncologyMar 2026
NCT06965933LidocainePhase 4Regional AnesthesiaOtherApr 2026
NCT05182385VenetoclaxPhase 1ALL, Recurrent, AdultOncologyApr 2026
NCT03933735TNB-383BPhase 1Multiple MyelomaOncologyMay 2026
NCT06979141LidocainePhase 3CoughOtherJun 2026
NCT03539536Telisotuzumab Vedotin (ABBV-399)Phase 2Non-small Cell Lung CancerOncologyJul 2026
NCT02099058Telisotuzumab Vedotin (ABBV-399)Phase 1Advanced Solid Tumors CancerOncologyAug 2026
NCT07032597LidocainePhase 3Mid Face Volume DeficitOtherSep 2026
NCT06953934ABBV-932Phase 1Healthy VolunteerOtherSep 2026
NCT02988960Budigalimab (ABBV-181)Phase 1Advanced Solid Tumors CancerOncologySep 2026
NCT02988960Giloralimab (ABBV-927)Phase 1Advanced Solid Tumors CancerOncologySep 2026
NCT06487559Budigalimab (ABBV-181)Phase 1Hepatocellular Carcinoma (HCC)OncologySep 2026
NCT06487559LivmoniplimabPhase 1Hepatocellular Carcinoma (HCC)OncologySep 2026
NCT07222709ABBV-1042Phase 1Healthy VolunteerOtherSep 2026
NCT05566054VenetoclaxPhase 2Acute Monocytic LeukemiaOncologySep 2026
NCT07008846UpadacitinibPhase 3Moderate to Severe Rheumatoid ArthritisImmunologySep 2026
NCT05657639VenetoclaxPhase 2Acute Myeloid LeukemiaOncologyOct 2026
NCT07649954NacresertibPhase 1Healthy VolunteerOtherOct 2026
NCT07730554Trenibotulinumtoxine (AGN-151586)Phase 2Forehead LinesOtherOct 2026
NCT07680686UbrogepantPhase 1Healthy VolunteerOtherOct 2026
NCT05336812VenetoclaxPhase 2Chronic Lymphocytic LeukemiaOncologyOct 2026
NCT07661758LidocainePhase 3Intravenous LidocaineOtherNov 2026
NCT05822752Budigalimab (ABBV-181)Phase 2Hepatocellular CarcinomaOncologyNov 2026
NCT04895436VenetoclaxPhase 2Chronic Lymphocytic Leukemia (CLL)OncologyNov 2026
NCT03980171VenetoclaxPhase 1Follicular LymphomaOncologyNov 2026
NCT05226455VenetoclaxPhase 1MDSOncologyNov 2026
NCT05053659VenetoclaxPhase 1Relapsed Non Hodgkin LymphomaOncologyNov 2026
NCT05822752LivmoniplimabPhase 2Hepatocellular CarcinomaOncologyNov 2026
NCT06389136UpadacitinibPhase 3Atopic DermatitisImmunologyNov 2026
NCT06389136UpadacitinibPhase 3Atopic DermatitisImmunologyNov 2026

The 60 nearest readouts of 582 trials; the rest in the app.

From the company's SEC filings

Cash of $10.8bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Targets

MET (2) CD40 (2) BCL2 (2) CALCRL (2) TYK2 (2) JAK3 (2) JAK2 (2) JAK1 (2) SNAP25 (2) BCL2L1 (2) BCMA (2) Tubulin (2)

Companies with the same targets

Pfizer AstraZeneca Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical BeOne Medicines Ascentage Pharma Group Johnson & Johnson (Janssen) Exelixis Chia Tai Tianqing Pharmaceutical Group Novartis Sun Pharmaceutical Industries

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.